Vimarsana
Biggest News Aggregation in the World

Page 2 - Pfizer Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pfizer Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pfizer Ventures Today - Breaking & Trending Today

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology - Vimarsana News

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology

A sneak peek at the Rhode Island Life Sciences Hub summit - Vimarsana News

A sneak peek at the Rhode Island Life Sciences Hub summit

Hundreds of policymakers, thought leaders, and politicians are coming together at the R.I. convention center to discuss where Rhode Island fits in a multibillion-dollar industry.

British Patient Capital invests £10m into cancer-focused biotech - Vimarsana News

British Patient Capital invests £10m into cancer-focused biotech

British Patient Capital, the venture capital subsidiary of the British Business Bank, has invested £10m into Curve Therapeutics.

Source: cityam.com
Curve Therapeutics Raises £40.5M in Series A Funding - Vimarsana News

Curve Therapeutics Raises £40.5M in Series A Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Curve Therapeutics raises £40.5m to 'turbocharge' discovery platform - Vimarsana News

Curve Therapeutics raises £40.5m to 'turbocharge' discovery platform

Curve Therapeutics, a biotech developing an intracellular screening platform addressing complex disease targets, has closed its £40.5 million Series A financing.